CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1825-1835

  Bhutia, Yangzom D ^a   Hung, Sau Wai ^a   Patel, Bhavi ^a   Lovin, Dylan ^a   Govindarajan, Rajgopal ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN T1; GEMCITABINE; MICRORNA;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CELL TRANSPORT; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LYSOSOME; NONHUMAN; PANCREAS CANCER; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT PROTEINS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79952221881     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2736     Document Type: Article

References (48)

1. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009;41:77-88.
2. Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010;16:673-82.
3. Huber-Ruano I, Pastor-Anglada M. Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity. Curr Drug Metab 2009;10:347-58.
4. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
5. Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine. Mol Cancer Ther 2008;7:2415-25.
6. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-57. (Pubitemid 28450036)
7. Lostao MP, Mata JF, Larrayoz IM, Inzillo SM, Casado FJ, Pastor-Anglada M. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett 2000;481:137-40.
8. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003;9:5000-8. (Pubitemid 37323307)
9. Hu H, Endres CJ, Chang C, Umapathy NS, Lee EW, Fei YJ, et al. Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol Pharmacol 2006;69:1542-53.
10. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999;91:1876-81.
11. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 2009;44:782-6.
12. Farrell JJ, Elsaleh H, Garcia M, Ammar A, Regine WF, Abrams R, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-95.
13. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006;66:3928-35.
14. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009;15:2913-9.
15. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004;10:6956-61. (Pubitemid 39383046)
16. Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, et al. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol 2007;293:R1809-22.
17. Govindarajan R, Endres CJ, Whittington D, LeCluyse E, Pastor-Anglada M, Tse CM, et al. Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am J Physiol Gastrointest Liver Physiol 2008;295:G570-80.
18. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 2009;10:R130.
19. Aymerich I, Pastor-Anglada M, Casado FJ. Long term endocrine regulation of nucleoside transporters in rat intestinal epithelial cells. J Gen Physiol 2004;124:505-12. (Pubitemid 39506286)
20. Valdes R, Fernandez-Veledo S, Aymerich I, Casado FJ, Pastor-Anglada M. TGF-beta transcriptionally activates the gene encoding the high-affinity adenosine transporter CNT2 in rat liver parenchymal cells. Cell Mol Life Sci 2006;63:2527-37 (Pubitemid 44722382)
21. Soler C, Garcia-Manteiga J, Valdes R, Xaus J, Comalada M, Casado FJ, et al. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB J 2001;15:1979-88. (Pubitemid 32848802)
22. Soler C, Felipe A, Garcia-Manteiga J, Serra M, Guillén- Gómez E, Casado FJ, et al. Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways. Biochem J 2003;375:777-83. (Pubitemid 37433528)
23. Klein K, Kullak-Ublick GA, Wagner M, Trauner M, Eloranta JJ. Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression. Am J Physiol Gastrointest Liver Physiol 2009;296:G936-47.
24. Gloeckner-Hofmann K, Guillen-Gomez E, Schmidtgen C, Porstmann R, Ziegler R, Stoss O, et al. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 2006;70:238-44. (Pubitemid 44154698)
25. Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J, et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 2004;112:959-66. (Pubitemid 39507001)
26. Hamilton SR, Yao SY, Ingram JC, Hadden DA, Ritzel MW, Gallagher MP, et al. Subcellular distribution and membrane topology of the mammalian concentrative Na+-nucleoside cotransporter rCNT1. J Biol Chem 2001;276:27981-8.
27. Valdes R, Casado FJ, Pastor-Anglada M. Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochem Biophys Res Commun 2002;296:575-9.
28. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008;27:5959-74.
29. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010;79:351-79.
30. Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005;68:1636-44. (Pubitemid 41654347)
31. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005;65:6835-42. (Pubitemid 41060722)
32. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 2000;60:6080-8.
33. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000;60:6075-9.
34. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 2001;61:1065-72. (Pubitemid 32174426)
35. Pegoraro L, Bernengo MG. Thymidine kinase, deoxycytidine kinase and deoxycytidylate deaminase activities in phytohaemagglutinin stimulated human lymphocytes. Exp Cell Res 1971;68:283-90.
36. Wan CW, Mak TW. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells. Cancer Res 1978;38:2768-72.
37. Powell BL, Gregory BW, Evans JK, White JC, Lyerly ES, Chorley HM, et al. Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia 1991;5:1037-42.
38. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro- 2′-deoxycytidine). Cancer Res 1990;50:4417-22. (Pubitemid 20225688)
39. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21. (Pubitemid 38610244)
40. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003;113:88-95. (Pubitemid 36999796)
41. Winter JM, Ting AH, Vilardell F, Baylin SB, Hruban RH, Kern SE, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008;14:412-8. (Pubitemid 351226108)
42. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009;69:5820-8.
43. Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 2010;70:2115-25.
44. Nishioka R, Itoh S, Gui T, Gai Z, Oikawa K, Kawai M, et al. SNAIL induces epithelial-to-mesenchymal transition in a human pancreatic cancer cell line (BxPC3) and promotes distant metastasis and invasiveness in vivo. Exp Mol Pathol.
45. Seidel B, Braeg S, Adler G, Wedlich D, Menke A. E- and N-cadherin differ with respect to their associated p120ctn isoforms and their ability to suppress invasive growth in pancreatic cancer cells. Oncogene 2004;23:5532-42. (Pubitemid 39044064)
46. Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, et al. Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009;69:6704-12.
47. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev 1998;12:95-106. (Pubitemid 28083661)
48. Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell. 2001;8:303-16. (Pubitemid 32831548)